Pharmaceutical Executive, in collaboration with Biofourmis, organized a roundtable of experts from various groups to discuss how digital medicine and pharmaceuticals are changing the trajectory of what drug development and clinical care look like together, with an emphasis on partnerships within digital health.
A modern healthcare ecosystem involves various stakeholders and many forms of complex data. Collaborations and a range of advanced approaches are essential to providing more uniform and complete healthcare to patients.
Genpact’s latest report, Life Sciences and Healthcare in the Age of Instinct, explores three major trends shaping the future of healthcare.
Education and knowledge transfer must be prioritized for industry to see sizable improvement in medical affairs.
The Medicare Part D cap won’t solve need for financial assistance.
Pharma companies and RPM manufacturers must work together to find solutions to make DCT more commonly available.
In today’s pharmaceutical market access landscape, payers are not the sole decision-makers in utilization management development.
A fresh look at how industry benchmarks can help fortify new drug launches to overcome today’s new market-entry barriers and higher expectations.
GenAI is on the precipice of breaking new ground in regulatory intelligence; making strategists more efficient by alleviating challenges, streamlining regulatory research and submission processes.
at some point, we won’t be seeing wall-to-wall COVID coverage anymore, but stories about the fallout. How can pharmaceutical brands prepare for what’s next?
Top industry experts weigh in on what the new year holds for the pharma industry.
New regulations may require regulators to explore new payment options.
Precision & Specialty Medicines are driving changes in the pharma development industry. We explore the changes these paradigms are having on the clinical trial space.
Significant challenges still lie ahead, but several specialists and a plethora of new technologies are well positioned to gather and analyze the evidence needed for diagnosing and treating rare diseases, writes Catherine Tak Piech.
Exploring the importance of analytics as a means of staying competitive in the commercial pharmaceutical market.
MIDD can pave new road for drug development.
Exploring those areas and functions where the application of generative artificial intelligence—through use cases borne out in practice—are demonstrating tangible value and driving life sciences innovation to new heights.
Creating a digital diagnostic that is supplemental and strategic to a company’s therapeutic asset requires due diligence to monetize the digital health innovation, or at least ensure optionality through the product development cycle.
Collaborative efforts among researchers, clinicians, and industry are essential to unlock the full potential of digital health in transforming the lives of people with Parkinson's disease.
A look into the traits that hiring managers of pharma companies should be searching for when hiring for a leadership role.
Virtual audits proving to be beneficial post-COVID despite continuing challenges.
How these actions can help brand teams form effective and sustainable relationships with patient communities
Pharma companies are now under increasing pressure, and increasingly willing, to offer a patient-centric approach. But with this increasing demand comes confusion about what patient-centered research actually is.
Patient support programs (PSPs) have an opportunity for growth and innovation.
Amid the shifting focus from primary care to specialty care, using data-driven tactics can create tailored campaigns and meaningful relationships with nurse practitioners and physician assistants.
Planning for a post-recession scenario is essential, ensuring companies are prepared to scale up when funding permits.